10-Q · May 14, 2026
Cabaletta Bio, Inc. (CABA) reported a net loss of $43.5 million in Q1 2026 with an EPS of -0.39, outperforming analyst expectations of -0.71 by 45.2%. Notably, the cash position decreased from $133.6 million at the end…
Earnings analysis · 10-Q
CABA earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Cabaletta's Q2 2026 EPS loss improved to -$0.34 from -$0.73 a year earlier, and $225.1 million of cash is expected to fund operations into mid-2027. However, six-month net loss increased to $94.5 million from $81.1…
Read full summary
Cabaletta's Q2 2026 EPS loss improved to -$0.34 from -$0.73 a year earlier, and $225.1 million of cash is expected to fund operations into mid-2027. However, six-month net loss increased to $94.5 million from $81.1 million, the filing newly identifies substantial doubt about the company's ability to continue as a going concern, and additional financing is required. Clinical progress in myositis is encouraging, but manufacturing dependence, external-control regulatory uncertainty, dilution and near-term funding risks remain significant.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.34
What stood out
-
Quarterly EPS Loss Narrowed
Q2 2026 diluted EPS was -$0.34, improving from -$0.39 in Q1 2026 and -$0.73 in Q2 2025. The year-over-year loss narrowed by $0.39 per share.
-
Cash Runway Extends Into Mid-2027
Cash and cash equivalents were $225.1 million at June 30, 2026. Management expects this balance to fund operations into mid-2027.
-
Clinical Investment Increased Losses
Six-month net loss increased to $94.5 million from $81.1 million in the prior-year period, a $13.4 million or 16.5% increase, reflecting continued investment in clinical development.
-
Capital Raised to Fund Development
The company raised approximately $140.2 million of net proceeds from a May 2026 equity offering and an additional $28.7 million through its ATM program during the six months ended June 30, 2026.
-
Myositis Endpoint Performance Positive
Management reported 80% registrational-endpoint performance, or 8 of 10 evaluable adult myositis patients, supporting continued advancement of the rese-cel program.
What to watch
-
Going-Concern Risk Newly Identified
The company explicitly states that substantial doubt exists about its ability to continue as a going concern for at least 12 months following the filing. Although cash was $225.1 million and is expected to fund operations into mid-2027, management says substantial additional financing will be required.
-
Further Equity Dilution Risk
Equity financing has created substantial dilution: the May 2026 offering issued 51,725,000 shares for approximately $140.2 million of net proceeds, while the ATM program issued 10,132,367 shares for $28.7 million during the first six months of 2026.
-
Near-Term Warrant Financing Uncertain
As of June 30, 2026, 47,815,090 common-stock warrants remained outstanding, with an exercise price of $2.50 per share and expiration on September 12, 2026. If exercised for cash, the company could receive approximately $120.0 million, but unexercised warrants would provide no proceeds.
-
Lonza Manufacturing Dependency Updated
The company is reliant on Lonza for current manufacturing activities. The Lonza Agreement has an initial five-year term, but Lonza may terminate with written notice subject to a three-month ramp-down period, potentially disrupting clinical supply and commercial-readiness plans.
-
External-Control Regulatory Risk
FDA feedback in March 2026 identified potential baseline differences between the RESET-Myositis trial and its proposed registry external control, including diagnosis classification and refractory definitions, as well as missing data. The planned registrational study uses a 16-week primary endpoint, so an unsuitable external control could require additional data or a randomized trial.
-
Limited Target Engagement Risk
CAAR T candidates target approximately 0.01% to 1% of a patient's B cells, creating a risk that insufficient target engagement will prevent adequate engraftment and elimination of pathogenic B cells. This could delay development or require product and manufacturing changes.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management expects cash and cash equivalents of $225.1 million as of June 30, 2026 to fund operations into mid-2027, but states that substantial additional financing will be required and that substantial doubt exists about continuing as a going concern for at least 12 months following the filing.
Earlier filings 4
10-K · March 23, 2026
Cabaletta (CABA) is a late clinical‑stage biotech focused on its CABA® CARTA platform and lead product rese-cel, pursuing registrational cohorts across multiple autoimmune indications. The 2025 filing highlights…
10-K · March 31, 2025
Cabaletta remains a clinical-stage CAR T company focused on its CABA® platform and lead candidate rese-cel, with multiple IND clearances and early clinical signals across autoimmune indications. The company reports…
10-Q · November 14, 2024
Cabaletta reported a wider quarterly loss as R&D investment accelerated; GAAP net loss for the three months ended September 30, 2024 was $30,629 (EPS $0.62 loss) versus $16,448 (EPS $0.37 loss) in the prior-year…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.